Literature DB >> 2338029

Pharmacokinetics of sulbactam/ampicillin in humans after intravenous and intramuscular injection.

S Ripa1, L Ferrante, M Prenna.   

Abstract

We investigated the pharmacokinetic properties of sulbactam/ampicillin (S/A), after intravenous (0.5/1.0 and 1.0/2.0 g) and intramuscular (0.5/1.0 g) coadministration in 10 male subjects. After 1.0/2.0 g intravenous doses of S/A the half-lives (t1/2 beta) were 1.14 +/- 0.14/1.09 +/- 0.16 h. The values for plasma clearance (CLp) were 198.83 +/- 26.27/250.33 +/- 39.28 ml/min and the renal clearance (Clr) 173.50 +/- 19.66/208.80 +/- 26.43 ml/min. The post distributive volumes (V beta) were 19.67 +/- 3.24/23.56 +/- 5.76 liters. Similar values were obtained after 0.5/1.0 g of S/A intravenous coinjection. After 0.5/1.0 g intramuscular coadministration the t1/2 beta values were 1.26 +/- 0.18/1.20 +/- 0.15 h. The values for Clp were 208.00 +/- 28.73/243.17 +/- 33.24 ml/min, for Clr 179.50 +/- 20.26/202.67 +/- 27.61 ml/min and for V beta 22.27 +/- 4.12/25.30 +/- 4.87 liters. The renal clearance of sulbactam is comparable to that of ampicillin and both clearances are greater than the glomerular filtration rate, suggesting active renal tubular secretion of the two drugs. The large volumes of distribution, and the ratio K12/K21 = 0.5 show the extensive distribution of the two drugs into extracellular fluids. The very similar values of the pharmacokinetic parameters of sulbactam and ampicillin confirm that the kinetics of the two drugs closely resemble one another.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2338029     DOI: 10.1159/000238765

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  8 in total

1.  Pharmacokinetics of ampicillin and sulbactam in pediatric patients.

Authors:  M C Nahata; V I Vashi; R N Swanson; M A Messig; M Chung
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis.

Authors:  D Herbert; C N Paramasivan; P Venkatesan; G Kubendiran; R Prabhakar; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

3.  Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.

Authors:  M K Lacy; W Lu; X Xu; P R Tessier; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

4.  Evolutionary Trajectories toward High-Level β-Lactam/β-Lactamase Inhibitor Resistance in the Presence of Multiple β-Lactamases.

Authors:  Fredrika Rajer; Lisa Allander; Philip A Karlsson; Linus Sandegren
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

5.  Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.

Authors:  Elena Soto; Satoshi Shoji; Chieko Muto; Yoshiro Tomono; Scott Marshall
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

6.  Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design.

Authors:  Adriana Tremoulet; Jennifer Le; Brenda Poindexter; Janice E Sullivan; Matthew Laughon; Paula Delmore; Andrea Salgado; Sandy Ian-U Chong; Chiara Melloni; Jamie Gao; Daniel K Benjamin; Edmund V Capparelli; Michael Cohen-Wolkowiez
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.938

7.  Effects of dosing frequency on the clinical efficacy of ampicillin/sulbactam in Japanese elderly patients with pneumonia: A single-center retrospective observational study.

Authors:  Tomokazu Suzuki; Erika Sugiyama; Kenji Nozawa; Masataka Tajima; Kyoka Takahashi; Masayoshi Yoshii; Hidenori Suzuki; Vilasinee H Sato; Hitoshi Sato
Journal:  Pharmacol Res Perspect       Date:  2021-04

8.  Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii.

Authors:  Shixing Zhu; Jiayuan Zhang; Chu Song; Yuwei Liu; Charles Oo; M Tobias Heinrichs; Zhihua Lv; Yuanqi Zhu; Sherwin K B Sy; Pan Deng; Mingming Yu
Journal:  Front Microbiol       Date:  2022-09-23       Impact factor: 6.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.